Fractyl Health, Inc. (NASDAQ:GUTS) Shares Acquired by Bank of New York Mellon Corp

Bank of New York Mellon Corp grew its holdings in Fractyl Health, Inc. (NASDAQ:GUTS) by 27.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 41,448 shares of the company’s stock after purchasing an additional 8,886 shares during the period. Bank of New York Mellon Corp’s holdings in Fractyl Health were worth $85,000 as of its most recent SEC filing.

A number of other large investors also recently made changes to their positions in GUTS. Jane Street Group LLC acquired a new position in shares of Fractyl Health during the 3rd quarter worth $25,000. JPMorgan Chase & Co. raised its stake in shares of Fractyl Health by 335.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 14,807 shares of the company’s stock valued at $37,000 after acquiring an additional 11,406 shares in the last quarter. HighTower Advisors LLC acquired a new stake in Fractyl Health in the 3rd quarter worth approximately $38,000. XTX Topco Ltd bought a new stake in Fractyl Health during the third quarter worth approximately $51,000. Finally, BNP Paribas Financial Markets grew its holdings in Fractyl Health by 54.1% during the third quarter. BNP Paribas Financial Markets now owns 21,072 shares of the company’s stock valued at $53,000 after purchasing an additional 7,397 shares during the last quarter.

Fractyl Health Stock Down 1.6 %

Fractyl Health stock opened at $1.24 on Monday. The company has a debt-to-equity ratio of 0.60, a current ratio of 5.58 and a quick ratio of 5.57. Fractyl Health, Inc. has a fifty-two week low of $1.16 and a fifty-two week high of $7.89. The firm has a fifty day moving average price of $1.53 and a two-hundred day moving average price of $2.04. The firm has a market cap of $60.66 million and a price-to-earnings ratio of -0.10.

Fractyl Health (NASDAQ:GUTS) last posted its quarterly earnings data on Monday, March 3rd. The company reported ($0.52) earnings per share for the quarter, missing the consensus estimate of ($0.44) by ($0.08). As a group, analysts forecast that Fractyl Health, Inc. will post -1.61 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Separately, Morgan Stanley dropped their price target on shares of Fractyl Health from $18.00 to $10.00 and set an “overweight” rating on the stock in a research report on Monday, February 3rd.

Insiders Place Their Bets

In other Fractyl Health news, CEO Harith Rajagopalan sold 90,972 shares of the company’s stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $1.82, for a total value of $165,569.04. Following the completion of the transaction, the chief executive officer now owns 491,329 shares of the company’s stock, valued at $894,218.78. This represents a 15.62 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Jay David Caplan sold 22,346 shares of Fractyl Health stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $1.81, for a total value of $40,446.26. Following the sale, the insider now directly owns 153,544 shares in the company, valued at $277,914.64. The trade was a 12.70 % decrease in their position. The disclosure for this sale can be found here.

About Fractyl Health

Fractyl Health, Inc, a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.